

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 November 2023 (09.11.2023)



(10) International Publication Number
WO 2023/215520 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61P 17/14* (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2023/021067

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:
04 May 2023 (04.05.2023)

Published:

— with international search report (Art. 21(3))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/338,320 04 May 2022 (04.05.2022) US

(71) Applicant: SUN PHARMACEUTICAL INDUSTRIES,
INC. [US/US]; 2 Independence Way, Princeton, NJ 08540
(US).

(72) Inventor: CASSELLA, James, V.; 7 Little Point Street,
Essex, CT 06426 (US).


(74) Agent: ABELLEIRA, Susan, M. et al.; FOLEY HOAG
LLP, 155 Seaport Boulevard, Boston, MA 02210-2600
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: DOSAGE REGIMENS FOR TREATMENT WITH DEUTERATED JAK INHIBITORS

(57) Abstract: Disclosed is a method of treating in a subject a diseases, disorders or conditions mediated alone or in part by Janus Associated Kinases that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an effective amount of Compound (I): or a pharmaceutically acceptable salt thereof.



Compound (I)



WO 2023/215520 A1